Daraxonrasib receives FDA National Priority Voucher

Daraxonrasib is among the first recipients of the FDA Commissioner's National Priority Voucher (CNPV) pilot, allowing a 1–2 month review once a marketing application is submitted.

In October 2025 the FDA announced the first recipients of its Commissioner's National Priority Voucher (CNPV) pilot program, and daraxonrasib was among them. The voucher allows the sponsor to receive an expedited 1–2 month review once the marketing application is submitted.

This was a further important regulatory endorsement for daraxonrasib following Breakthrough Therapy Designation, reflecting the agency's focus on pancreatic cancer as an area of very high unmet medical need.